

**GEOVAX LABS, INC.**  
**Condensed Consolidated Statements of Operations Information**  
*(amounts in thousands, except per share data)*

	Three Months Ended		Nine Months Ended	
	September 30,		September 30,	
	2024	2023	2024	2023
Revenue from government contract	\$ 2,789	\$ -	\$ 3,090	\$ -
Operating expenses:				
Research and development	7,402	6,948	16,105	14,487
General and administrative	1,241	1,652	3,785	4,562
	<u>8,643</u>	<u>8,600</u>	<u>19,890</u>	<u>19,049</u>
Loss from operations	(5,854)	(8,600)	(16,800)	(19,049)
Other income (expense)	39	191	70	675
Net loss	<u>\$ (5,815)</u>	<u>\$ (8,409)</u>	<u>\$ (16,730)</u>	<u>\$ (18,374)</u>
Loss per common share	<u>\$ (0.91)</u>	<u>\$ (4.75)</u>	<u>\$ (4.52)</u>	<u>\$ (10.42)</u>

**Condensed Consolidated Balance Sheet Information**  
*(amounts in thousands, except common share information)*

	Sep 30,	Dec 31,
	2024	2023
Assets		
Cash and cash equivalents	\$ 8,593	\$ 6,453
Other current assets	2,276	1,433
Total current assets	<u>10,869</u>	<u>7,886</u>
Property and other assets	243	1,397
Total assets	<u>\$ 11,112</u>	<u>\$ 9,283</u>
Liabilities and stockholders' equity		
Total liabilities	\$ 2,608	\$ 3,520
Stockholders' equity	8,504	5,763
Total liabilities and stockholders' equity	<u>\$ 11,112</u>	<u>\$ 9,283</u>
Common shares outstanding	8,609,308	1,977,152